VEGFA and retinopathy of prematurity: Therefore, because of the evidence for ROP recurrence and continued safety concerns as well as the disputed risk-benefit profiles, further tests of anti-VEGF therapy for ROP will require careful monitoring of both safety and efficacy to determine whether there is a place for such agents in the treatment of ROP preterm infants.